Radius Health (NASDAQ:RDUS) on Wednesday said it had entered into new agreements for the expansion of its Tymlos injection to treat osteoporosis - a condition in which bones become weak and brittle - ...

Osteoporosis-related fractures are an important health concern because of related morbidity, mortality, and cost. 2 Bruce Mitlak, M.D., the Chief Medical Officer of Radius, emphasized that "30% of all ...

Results showed that treatment with abaloparatide for 12 months resulted in significant increases in bone mineral density compared with placebo. The Food and Drug Administration (FDA) has approved ...

Abaloparatide-Patch patient assessment study results demonstrated high patient acceptability and self-administration accuracy over a 29-day period Levels of PINP, a biomarker for bone formation, after ...

Labatec Pharma SA: Switzerland and the MENA region including Bahrain, Iraq, Jordan, Kuwait, Oman, Qatar, Saudi Arabia, UAE, Algeria, and Morocco Pharmbio Korea Inc.: South Korea Biosidus: Colombia, ...

(RTTNews) - Radius Health Inc. (RDUS) announced positive results from the ATOM Phase 3 Study evaluating TYMLOS or abaloparatide 80mcg subcutaneous (SC) for use in males with osteoporosis. The company ...

Dr. Roach: In the past, I have been treated for osteoporosis, but still had a spinal fracture last year that required surgery. My endocrinologist suggested Tymlos because it encourages bone growth ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Men with osteoporosis receiving daily injections of abaloparatide had greater increases in bone ...

You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. DEAR DR. ROACH: In the past, I have been treated for osteoporosis, but still ...